Bloom Burton & Co.

Bloom Burton & Co. is a Canadian investment firm dedicated to accelerating returns in the healthcare sector for both investors and companies. The firm offers a comprehensive suite of services, including capital raising, mergers and acquisitions advisory, equity research, strategic advisory, and company creation and incubation. Their experienced team comprises medical, scientific, industry, and capital markets professionals who perform in-depth diligence, assisting clients in achieving optimal monetization events. Bloom Burton & Co. is a member of the Canadian Investment Regulatory Organization (CIRO) and the Canadian Investor Protection Fund (CIPF).

The firm's investment focus spans various stages, from seed to pre-IPO, encompassing buyouts, turnarounds, and distressed situations. They primarily invest in private equity and venture capital within the healthcare sector, targeting industries such as biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition, and wellness. Geographically, Bloom Burton & Co. concentrates its efforts in Canada and the United States.

Bloom Burton & Co. has a proven track record in the healthcare sector, having advised on numerous mergers and acquisitions. Notable transactions include advising on the sale of Medicago, Inc. and YM BioSciences, Inc., as well as the acquisition of Embryotech Laboratories, Inc. by Hamilton Thorne Ltd. Their strategic approach and deep industry knowledge have established them as a leading firm in healthcare investment banking.